Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.
Thomas W. Sedlak,Leslie G. Nucifora,Minori Koga,Lindsay S. Shaffer,Cecilia Higgs,Teppei Tanaka,AM Wang,Jennifer M. Coughlin,Peter B. Barker,Jed W. Fahey,Akira Sawa +10 more
- 01 Jan 2017
- Vol. 3, Iss: 4, pp 214-222
TL;DR: The value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences sulforaphane has on functional measures that are altered in neuropsychiatric disorders are suggested.
read more
Abstract: Schizophrenia and other neuropsychiatric disorders await mechanism-associated interventions. Excess oxidative stress is increasingly appreciated to participate in the pathophysiology of brain disorders, and decreases in the major antioxidant, glutathione (GSH), have been reported in multiple studies. Technical cautions regarding the estimation of oxidative stress-related changes in the brain via imaging techniques have led investigators to explore peripheral GSH as a possible pathological signature of oxidative stress-associated brain changes. In a preclinical model of GSH deficiency, we found a correlation between whole brain and peripheral GSH levels. We found that the naturally occurring isothiocyanate sulforaphane increased blood GSH levels in healthy human subjects following 7 days of daily oral administration. In parallel, we explored the potential influence of sulforaphane on brain GSH levels in the anterior cingulate cortex, hippocampus, and thalamus via 7-T magnetic resonance spectroscopy. A significant positive correlation between blood and thalamic GSH post- and pre-sulforaphane treatment ratios was observed, in addition to a consistent increase in brain GSH levels in response to treatment. This clinical pilot study suggests the value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences sulforaphane has on functional measures that are altered in neuropsychiatric disorders.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.
Henry Jay Forman,Hongqiao Zhang +1 more
TL;DR: In this article, a review of the relationship between oxidative stress, redox signalling and disease, the mechanisms through which oxidative stress can contribute to pathology, how antioxidant defences work, what limits their effectiveness, and how antioxidant defenses can be increased through physiological signalling, dietary components and potential pharmaceutical intervention.
Broccoli or Sulforaphane: Is It the Source or Dose That Matters?
TL;DR: This review evaluates the relationships between formulation (e.g., plants, sprouts, beverages, supplements), bioavailability and efficacy, and the doses of glucoraphanin and/or sulforaphane that have been used in pre-clinical and clinical studies and pays special attention to the challenges for better integration of animal model andclinical studies.
Oxidative Stress and Osteoporosis.
TL;DR: In this article, a diet rich in whole plant foods with high antioxidant content along with antioxidant-preserving lifestyle changes may improve bone mineral density and reduce the risk of fragility-related fractures.
195
Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.
Evgeny A. Ermakov,Elena Dmitrieva,D. Parshukova,Daria V Kazantseva,Alisa R Vasilieva,L.P. Smirnova +5 more
TL;DR: It is suggested that not only antioxidants but also redox-regulated transcription factor-targeting drugs (including Nrf2 and FoxO activators or NF-κB inhibitors) have great promise in schizophrenia, but it is necessary to develop the stratification criteria of schizophrenia patients based on oxidative stress-related markers for the administration of red ox-correcting treatment.
The glutathione cycle shapes synaptic glutamate activity
Thomas W. Sedlak,Bindu D. Paul,Gregory M. Parker,Linda D. Hester,Adele M. Snowman,Yu Taniguchi,Atsushi Kamiya,Solomon H. Snyder,Akira Sawa +8 more
TL;DR: It is shown that drugs that inhibit generation of glutamate by the glutathione cycle elicit decreases in cytosolic glutamate and decreased miniature excitatory postsynaptic potential (mEPSC) frequency, while pharmacologically decreasing the biosynthesis of glutathion leads to increases in cytotoxic glutamate and enhanced mEpsC frequency.
129
References
Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues
TL;DR: The use of the foregoing analytical method in the determination of total and oxidized glutathione contents of rat blood, kidney, and liver gave values in good agreement with those obtained by previous investigators.
6.2K
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
TL;DR: The LCModel method analyzes an in vivo spectrum as a Linear Combination of Model spectra of metabolite solutions in vitro by using complete model spectra, rather than just individual resonances, to ensure maximum information and uniqueness are incorporated into the analysis.
3.7K
The Role of Oxidative Stress in Parkinson’s Disease
TL;DR: Animal models of PD have yielded some insights into the molecular pathways of neuronal degeneration and highlighted previously unknown mechanisms by which oxidative stress contributes to PD, but therapeutic attempts to target the general state of oxidative stress in clinical trials have failed to demonstrate an impact on disease progression.
Role of Oxidative Stress in Parkinson's Disease
TL;DR: NAD(P)H:quinone reductase (NQO1) and other antioxidant enzymes, whose gene expression are commonly under the regulation of the transcription factor Nrf2, can serve as target proteins utilized toward development of disease-modifying therapy for PD.
Glutathione dysregulation and the etiology and progression of human diseases.
Nazzareno Ballatori,Suzanne M. Krance,Sylvia Notenboom,Shujie Shi,Kim Tieu,Christine L. Hammond +5 more
TL;DR: The present report highlights and integrates the growing connections between imbalances in GSH homeostasis and a multitude of human diseases and suggests the high GSH content makes cancer cells chemoresistant, which is a major factor that limits drug treatment.